Bdnf-hypersecreting human umbilical cord blood mesenchymal stem cells promote erectile function in a rat model of cavernous nerve electrocautery injury

Song, Lujie; Zhu, Jianqiang; Cui, Zhiqiang; Liu, Yang; Fu, Qiang; Xu, Yue-Min; Lian, Hongkai

doi:10.1016/j.urols.2015.06.260

Cited by 1 publication

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14–18,20–26,30,31,34–39,41 Usually, this involved using a non-serrated hemostat away from major pelvic ganglion (MPG). In five studies, cavernous nerve injury was caused by transection injury, 13,32,33,38,40 in two studies electric coagulation, 19,27 and in one study Cryo-injury 28 was used.…”

Section: Resultsmentioning

confidence: 99%

“…Some studies used certain co-interventions or modifications to enhance the effect of stem cell intervention. Co-interventions included brain-derived neurotrophic factor (BDNF) in six studies; 14,27,30,34,37,41 oral Icariside II (ICA II) in two studies; 13,22 and low shock wave therapy and oral Udenafil were used in one study each. 26,34 Modifications included use of fibrin scaffolds, Matrixen (biocompatible polymer), exosomes, nanotechnology, and super-paramagnetic iron oxide nanoparticles.…”

Section: Resultsmentioning

confidence: 99%

“…It was used in 17 studies. 13,14,16–18,20,21,23,24,27–30,35,38–40 The usual technique for IC injections (ICIs), included rolling up the prepuce to expose the penis and injecting to the lateral aspect of the penis. The needle was inserted around 3–4 mm.…”

Section: Resultsmentioning

confidence: 99%

“…ICP and MAP ratio was evaluated from 26 studies; 13–37,39 3 studies did not provide ICP/MAP ratio values. 38,40,41 We found mean ICP/MAP ratio was higher in stem cell group (0.51) compared with BCNI group (0.25).…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Is there a role for stem cell therapy in erectile dysfunction secondary to cavernous nerve injury? Network meta-analysis from animal studies and human trials

Wani

Prasad

Webb

et al. 2022

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Introduction: We carried out systematic review and network meta-analysis to investigate the role of stem cell therapy (SCT) in the management of erectile dysfunction (ED) secondary to cavernous nerve injury in rats and post-radical prostatectomy (RP) in humans. Patients and Methods: The protocol was registered with PROSPERO database. We searched studies analyzing the efficacy of SCT for ED due to bilateral cavernous nerve injury (BCNI) in rats using Healthcare Databases Advanced Search (HDAS) Export software (MEDLINE, EMBASE, Scopus) from inception to September 2020. The outcome measurements, for 29 animal studies, were intracavernosal pressure (ICP), ICP/MAP (mean arterial pressure) ratio, and histological/molecular changes. All three available human trials evaluating SCT in post-RP ED were assessed for International Index for Erectile Function (IIEF) Score and Erection Hardness Score (EHS). Results: For ICP measurement, animal studies were divided into adipose-derived stem cells (ADSCs) subgroup and bone marrow–derived stem cells (BMSCs) subgroup. Pooled analysis of these studies showed a beneficial effect of SCT in improving erectile function in rats with BCNI using network meta-analysis (95% confidence interval, CI; p < 0.001). There was an increase in ICP/MAP ratio in stem cell groups (including co-intervention) compared with control BCNI group. Histological and molecular evaluation of penile tissue revealed an increase in neuronal nitric oxide synthase (nNOS), smooth muscle content, and anti-apoptotic activity. Human trials revealed improved IIEF (70–150% from baseline at 6 months) and EHS (80–200% from baseline). Conclusion: Our results confirm that SCT does improve the erectile function in rats having cavernous nerve injury. Similarly, early human results have shown promising results. PROSPERO registration ID: CRD42020201343.

show abstract